Patents Issued in July 27, 2017
  • Publication number: 20170209380
    Abstract: The present invention relates to a directly compressible composition for the production of tablets which comprise fine-grained polyvinyl alcohols (PVAs) and fine-grained microcrystalline celluloses (MCCs) in a co-mixture. The present invention also relates to the use of this mixture and to a process for the preparation thereof.
    Type: Application
    Filed: July 3, 2015
    Publication date: July 27, 2017
    Applicant: Merck Patent GmbH
    Inventors: Roberto OGNIBENE, Finn BAUER, Thorsten WEDEL, Guenter MODDELMOG
  • Publication number: 20170209381
    Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
    Type: Application
    Filed: September 6, 2016
    Publication date: July 27, 2017
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
  • Publication number: 20170209382
    Abstract: Methods, devices, and/or systems for providing a three-dimensional printing of a structure encapsulating a drug comprising at least one Zn(II) complexed with acrylate groups capable of forming a 3D structure and capable of encapsulating a drug.
    Type: Application
    Filed: January 17, 2017
    Publication date: July 27, 2017
    Inventors: Juan Noveron, Shokooh Bahadorzadeh
  • Publication number: 20170209383
    Abstract: The present invention relates to an oral formulation for promoting napping in a subject. The formulation may comprise an outer layer comprising a sedative and/or relaxant, and an inner layer comprising a stimulant.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Inventor: Micah S. Gerchenson
  • Publication number: 20170209384
    Abstract: An object is to provide a method of manufacturing a soft capsule that is enteric and excellent in formulation properties. An enteric soft capsule is manufactured by the following steps (a) and (b): (a) preparing an enteric capsule shell liquid comprising gelatin and low methoxyl pectin having a degree of amidation of 5 to 25%, and (b) encapsulating capsule fills using the enteric capsule shell liquid prepared in the step (a) by stamping. Preferably, the jelly strength of the gelatin is 160 to 300 Bloom, the degree of esterification of the low methoxy pectin is 20 to 40%, and the enteric capsule shell liquid comprises 30 to 35 parts by mass of the low methoxy pectin per 100 parts by mass of the gelatin.
    Type: Application
    Filed: October 6, 2015
    Publication date: July 27, 2017
    Inventors: Kazuhiko Watanabe, Hiroaki Hasegawa, Nahonori Inaba, Yoshiyuki Shimokawa, Kenji Kato
  • Publication number: 20170209385
    Abstract: Provided is an aqueous composition comprising (a) dispersed particles that comprise one or more ethylcellulose polymers and (b) one or more additives having molecular weight less than 220 g/mol, Hansen hydrogen bonding parameter greater than 11 MPa1/2 and less than 17.9 MPa1/2, Hansen total solubility parameter greater than 22 MPa1/2, and solubility in water greater than 2 g/L at 25° C. Also provided is a composition comprising particles having a coating, wherein said coating comprises 0-5% water by weight based on the weight of said coating, wherein said coating additionally comprises the ingredients (a) and (b).
    Type: Application
    Filed: July 2, 2015
    Publication date: July 27, 2017
    Applicant: Dow Global Technolgies LLC
    Inventors: True L. Rogers, Stacey L. Dean, Jason J. Folkenroth, David L. Malotky, Shari L. Workentine
  • Publication number: 20170209386
    Abstract: An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described. A method of the invention for encapsulating water soluble molecules using rapid, controlled precipitation is presented. Water soluble molecules—including peptides, proteins, DNA, RNA, non-biologic therapeutics, polysaccharide-based therapeutics (e.g., tobramycin) and imaging agents—precipitate into nano articles that are protected by a copolymer stabilizing agent. These particles may be covalently or non-covalently stabilized. The particles may be coated with an amphiphilic polymer, or processed into microparticles or larger monoliths. Post processing on the final construct may be conducted.
    Type: Application
    Filed: June 16, 2015
    Publication date: July 27, 2017
    Applicant: The Trustees of Princeton University
    Inventors: Robert F. Pagels, Robert K. Prud'homme
  • Publication number: 20170209387
    Abstract: Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. These can be formulated into nanoparticles and delivered safely and effectively for treatment of pancreatic cancer and other glutamine addicted cancers. Studies demonstrate that nanoparticle delivery of BPTES, relative to use of BPTES alone, can be safely administered and provides dramatically improved tumor drug exposure, resulting in greater efficacy. GLS inhibitors can be administered in higher concentrations with sub-100 nm nanoparticles, since the nanoparticles package the drug into “soluble” colloidal nanoparticles, and the nanoparticles deliver higher drug exposure selectively to the tumors due to the enhanced permeability and retention (EPR) effect. These factors result in sustained drug levels above the IC50 within the tumors for days, providing significantly enhanced efficacy compared to unencapsulated drug.
    Type: Application
    Filed: July 8, 2015
    Publication date: July 27, 2017
    Inventors: Justin Hanes, Barbara S. Slusher, Anne Le, Jie Fu, Qingguo Xu
  • Publication number: 20170209388
    Abstract: The present invention provides a method for preparing a reconstituted apolipoprotein B lipoparticle and the method comprises steps of (a) dissolving an apolipoprotein B and a lipid in a first buffer containing 2 M to 8 M urea and 1 wt % to 15 wt % amphiphilic compounds to form a mixture; and (b) dialyzing the mixture against a second buffer containing 0 M to 2M urea and 0 wt % to 0.5 wt % amphiphilic compounds for 1 to several times for lowering concentrations of the urea and the amphiphilic compounds in the mixture. The present invention further provides an apolipoprotein B lipoparticle and a use for the production of an apolipoprotein B lipoparticle used for delivering a hydrophobic substance.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventors: Chia-Ching Chang, Gong-Shen Chen, Tsai-Mu Cheng, Hsueh-Liang Chu
  • Publication number: 20170209389
    Abstract: Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed.
    Type: Application
    Filed: July 23, 2015
    Publication date: July 27, 2017
    Inventors: Landy Toth, Robert S. Schwartz
  • Publication number: 20170209390
    Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
    Type: Application
    Filed: June 29, 2015
    Publication date: July 27, 2017
    Inventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
  • Publication number: 20170209391
    Abstract: The present disclosure relates to a system for administering retinol into skin that ensures stability of retinol, reduces skin irritation of retinol, and continues to exert effects, wherein the system is a microneedle including microparticles containing retinol or retinol derivatives. The present disclosure further provides a method for manufacturing a retinol administration system that reduces skin irritation, exerts effects of retinol for a long time, and ensures stability of retinol very unstable to light, wet and temperature. The present disclosure further provides a method for administering retinol into skin using the microneedle.
    Type: Application
    Filed: April 23, 2015
    Publication date: July 27, 2017
    Applicant: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Woo-Sun SHIM, Dong-Chan KIM, Young-Min HWANG, Sun-Hwa LEE, Nae-Gyu KANG, Sun-Gyoo PARK, Cheon-Koo LEE
  • Publication number: 20170209392
    Abstract: This disclosure describes compounds that affect the olfactory responses of the honey bee mite (Varroa destructor) and methods of use thereof. The compounds do not kill Varroa destructor, and are therefore unlikely to generate Varroa destructor resistance, compared to an acaricide. The compounds can work in conjunction with other mite control approaches, such as a bottom board excluder and sticky board control devices, and can enhance the performance of other forms of mite control while decreasing disadvantages associated therewith.
    Type: Application
    Filed: March 24, 2015
    Publication date: July 27, 2017
    Applicants: SIMON FRASER UNIVERSITY, ORGANIZATION (ARO)
    Inventors: Erika Plettner, Victoria Soroker
  • Publication number: 20170209393
    Abstract: Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: R1 and R2 are independently hydrogen, (C1-C6)alkyl or —O(C1-C6)alkyl; or R1 and R2 together represent —CH?CH—CH?CH—; R3 is (C1-C6)alkyl; X is —CH?CH— or —C?C—; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the —X—(CH2)n— group; Y is —OR4, —CN, —C(?O)OR5, —C(?O)R5, or —C(?O)N(R6)2; R4 and R5 are independently selected from the group consisting of hydrogen, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —C(?O)—(C1-C6)alkyl, —C(?O)—(C1-C6)haloalkyl, —C(?O)—NH(C1-C6)alkyl, —C(?O)—N((C1-C6)alkyl)2,
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Inventors: WILLIAM D. SHRADER, ANDREW W. HINMAN, VIKTORIA KHEIFETS
  • Publication number: 20170209394
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: October 31, 2016
    Publication date: July 27, 2017
    Inventors: Alain D. BARON, Mark S. FINEMAN, Nigel R.A. BEELEY
  • Publication number: 20170209395
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Epitech Group S.r.l.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Publication number: 20170209396
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Application
    Filed: December 20, 2016
    Publication date: July 27, 2017
    Inventors: Clark P. Allphin, Michael DesJardin
  • Publication number: 20170209397
    Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to modulate autophagy and lipophagy. HMB is also administered to treat, prevent, inhibit, slow or reduce autophagy-mediated conditions or diseases.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 27, 2017
    Inventors: Naji Abumrad, John Rathmacher, Shawn Baier
  • Publication number: 20170209398
    Abstract: The present invention relates to an aqueous ibuprofen and paracetamol composition of pH 6.3-7.3 and to its use. The present invention relates to a method for preparing a combination product of ibuprofen and paracetamol. It also relates to the compositions for use as a medicament, especially for the treatment of pain and/or inflammation; especially for administration of the composition by intravenous injection.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 27, 2017
    Inventor: Thomas Jacobsen
  • Publication number: 20170209399
    Abstract: The present invention concerns the use of compounds for preventing and/or treating diabetes, for modulating glucose, insulin, and/or triglyceride levels; for reducing blood glucose level; for maintaining or increasing insulin level; for increasing insulin secretion; increasing insulin sensitivity; or decreasing insulin resistance in a subject. These novel uses have been found for compounds represented by Formula I and pharmaceutically acceptable salts. wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH.
    Type: Application
    Filed: October 8, 2015
    Publication date: July 27, 2017
    Inventors: Lyne GAGNON, Brigitte GROUIX
  • Publication number: 20170209400
    Abstract: Methods and formulations are provided for the treatment of localized edema, particularly localized edema resulting from chronic venous insufficiency. A metal ion sequestrant is topically administered to a subject afflicted with localized edema in combination with a permeation enhancer selected from methylsulfonylmethane and a combination of methylsulfonylmethane and dimethylsulfoxide. Topically administrable formulations for use in the aforementioned method are also provided.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Inventors: Rajiv BHUSHAN, Jerry GIN, Amit GOSWAMY
  • Publication number: 20170209401
    Abstract: This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of Type 1 Diabetes (T1D) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of T1D or AA are also provided.
    Type: Application
    Filed: September 25, 2015
    Publication date: July 27, 2017
    Inventors: Aziz GHAHARY, Reza B. JALILI, Runhangiz T. KILANI, Yunyuan LI
  • Publication number: 20170209402
    Abstract: The invention provides methods of using carboxy-cyclopropyl undecanol compounds and pharmaceutically acceptable salts thereof to treat liver disease and other medical disorders associated with elevated lipid levels in the liver. Exemplary carboxy-cyclopropyl undecanol compounds described herein include 1,11-bis-(1-carboxy-cyclopropyl)-undecan-6-ol and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 27, 2017
    Inventors: Jeffrey C. Hanselman, Rai Ajit K. Srivastava, Roger S. Newton
  • Publication number: 20170209403
    Abstract: The present invention provides a method for regulating aldehyde dehydrogenase 1 (ALDH1) comprises administering all-trans retinoic acid to a subject. Further, the present invention also provides a method for treating solid malignancy comprises administering all-trans retinoic acid to a subject, providing a new choice in current cancer treatment.
    Type: Application
    Filed: January 27, 2016
    Publication date: July 27, 2017
    Inventors: Cheng-Yang Chou, Yi-Hui Wu, Yu-Fang Huang
  • Publication number: 20170209404
    Abstract: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes.
    Type: Application
    Filed: January 10, 2017
    Publication date: July 27, 2017
    Inventors: Chongxi Yu, Lina XU
  • Publication number: 20170209405
    Abstract: A combination of antioxidants is proposed as a supplement based on the best available clinical data. The present invention proposes a research-driven approach premised on the basic tenet that there are multiple antioxidant systems and various rate limiting steps. According to the present invention, specific combinations can influence the oxidative process in a way that cannot be achieved by any one individual molecule. It is an object of the present invention to develop and evaluate various combinations of antioxidants in order to determine which combinations are most effective in the treatment of specific conditions. It is a further object of the present invention to use clinical data to determine which combinations of antioxidants consistently yield clinically viable results.
    Type: Application
    Filed: November 17, 2016
    Publication date: July 27, 2017
    Inventor: Abraham Fouad JALBOUT
  • Publication number: 20170209406
    Abstract: An external wound-healing agent includes, as an active ingredient, at least one compound of a glycerol alkyl ester represented by Formula (I) or a diglycerol alkyl ester represented by Formula (II).
    Type: Application
    Filed: July 15, 2015
    Publication date: July 27, 2017
    Applicant: Mitsui Chemicals, Inc.
    Inventors: Naosuke Kunimoto, Kenichi Suzuki, Kouya Kojima, Akira Hasegawa, Yasufumi Tsuchiya, Jun Kamada, Satoshi Yamasaki, Goro Kuwamura, Daisuke Hasegawa
  • Publication number: 20170209407
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Application
    Filed: December 6, 2016
    Publication date: July 27, 2017
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • Publication number: 20170209408
    Abstract: HSP 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical compositions can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof. In particular embodiments, the weight loss agent is co-administered with leptin or a leptin analog.
    Type: Application
    Filed: April 3, 2015
    Publication date: July 27, 2017
    Inventors: Umut Özcan, Isin Cakir, Serkan Cabi
  • Publication number: 20170209409
    Abstract: Provided herein are embodiments related to metered dose inhalers and formulations for such inhalers. In some embodiments, the inhalers are configured so as to allow a more comfortable experience for the subject receiving the formulation. In some embodiments, the formulation comprises various ingredients, such as terpenes and/or waxes, which can further enhance the level of comfort for the subject receiving the formulation.
    Type: Application
    Filed: June 16, 2015
    Publication date: July 27, 2017
    Inventors: Michael S. Hartman, James V.C. Boyles
  • Publication number: 20170209410
    Abstract: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Application
    Filed: January 26, 2017
    Publication date: July 27, 2017
    Inventors: Manojkumar Ramprasad SHUKLA, Ankush Gangaram SARDE, Rajeshkumar Maganlal LORIYA, Vipul Dilip PACHPUTE, Navnath Bajirao WALKE, Talha Hussain KHAN, Sanjeev Anant KULKARNI, Venkata P. PALLE, Rajender Kumar KAMBOJ
  • Publication number: 20170209411
    Abstract: The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the ?-amyloid protein (A?) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of A? in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered.
    Type: Application
    Filed: July 28, 2014
    Publication date: July 27, 2017
    Applicant: National Chung Hsing University
    Inventors: Hong-Lin Su, Chia-Yu Chang, Shiaw-Min Hwang, Huai-En Lu, Horng-Jyh Harn, Shinn-Zong Lin, Ping-Shan Lai
  • Publication number: 20170209412
    Abstract: The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Inventors: Megbubah Essack, Vladimir Bajic, Aleksandar Radovanovic
  • Publication number: 20170209413
    Abstract: Embodiments disclosed herein provide methods for treating and/or ameliorating symptoms of certain neurological diseases. The methods encompass administration of compositions comprising 1,2-dithiolane-4-carboxylic acid (asparagusic acid) and derivatives and condensation products thereof.
    Type: Application
    Filed: January 26, 2017
    Publication date: July 27, 2017
    Inventor: Joseph WREEN
  • Publication number: 20170209414
    Abstract: Crystalline micronized particulate of a glycopyrronium salt may be prepared by hydrodynamic cavitation. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
    Type: Application
    Filed: January 19, 2017
    Publication date: July 27, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Stephen P. DAVANZO, Barry E. NALL, Timothy J. ROUSE, Michele MIOZZI
  • Publication number: 20170209415
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional anti-addictive compositions in the treatment of nicotine addiction and related disorders.
    Type: Application
    Filed: September 6, 2016
    Publication date: July 27, 2017
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Phil Skolnick
  • Publication number: 20170209416
    Abstract: Compositions having at least one flavonoid of natural or synthetic origin in association with melatonin to increase the effectiveness of chemotherapeutic treatments used in human and veterinary medicine for the treatment of tumours are described. The compositions are in particular for the treatment of tumours resistant to the chemotherapeutic agents currently in use. The at least one flavonoid is selected from rutin, oxerutin, diosmin and hesperidin, preferably rutin.
    Type: Application
    Filed: March 5, 2015
    Publication date: July 27, 2017
    Inventor: Giovanni MOGNA
  • Publication number: 20170209417
    Abstract: The invention relates to the chemical and pharmaceutical industry and consists of a rectal gel substance for treating diseases of the intestinal/digestive tract, including nonspecific ulcerative colitis, Crohn's disease, fistulae, etc., and also complications during the course of treatment of said diseases. The invention provides an antimicrobial and antiprotozoal effect and has good penetration capabilities. The technical result achieved by carrying out the claimed invention consists in increasing the effectiveness of treating non-infectious inflammatory diseases of the intestinal/digestive tract, and in shortening the duration of treatment. Said technical result is achieved by means of a polycomplex gel for treating diseases of the intestinal/digestive tract, said gel containing metronidazole and thymogen as active substances, and containing the following auxiliary substances, in the following composition and ratio of components, in grams, with a total mass of gel of 150 grams: metronidazole: 0.
    Type: Application
    Filed: September 23, 2014
    Publication date: July 27, 2017
    Inventor: Genrikh Markovich KHOROVETS
  • Publication number: 20170209418
    Abstract: The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.
    Type: Application
    Filed: January 25, 2016
    Publication date: July 27, 2017
    Inventors: David Frederick Woodward, Weizhen Wang
  • Publication number: 20170209419
    Abstract: A method of treating a hyperoxia induced disease or disorder associated with GSNO deficiency in a subject in need thereof includes administering to the subject a therapeutically effective amount of GSNO or a GSNO promoting agent.
    Type: Application
    Filed: January 27, 2017
    Publication date: July 27, 2017
    Inventors: Thomas M. Raffay, Benjamin M. Gaston
  • Publication number: 20170209420
    Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a polyether moiety at the 4?-position of the phenyl ring of the compound.
    Type: Application
    Filed: February 3, 2017
    Publication date: July 27, 2017
    Applicant: University of Florida Research Foundation, Inc.
    Inventor: Raymond J. Bergeron, JR.
  • Publication number: 20170209421
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Publication number: 20170209422
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Publication number: 20170209423
    Abstract: Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventor: Gregory Notte
  • Publication number: 20170209424
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Application
    Filed: January 3, 2017
    Publication date: July 27, 2017
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
  • Publication number: 20170209425
    Abstract: A method of treating non-neurodegenerative pathologies associated with derangement in brain-derived neurotrophic factor signaling in the brain stem includes administering to the subject an amount of at least one ampakine effective to increase brain-derived neurotrophic factor nodose sensory neurons of the subject.
    Type: Application
    Filed: October 3, 2016
    Publication date: July 27, 2017
    Inventor: David M. Katz
  • Publication number: 20170209426
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Publication number: 20170209427
    Abstract: The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provides packages, therapeutic packages and pharmaceutical compositions, comprising one or more unit doses of 0.5-1.5 mg laquinimod for treating or delaying disease progression in a subject afflicted with HD. Also disclosed is use of laquinimod in the manufacture of a medicament comprising one or more unit doses of 0.5-1.5 mg laquinimod for use in treating or delaying disease progression in a subject afflicted HD.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 27, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anna Kristina Sveinsdotter Teige Wickenberg, Esther Lukasiewicz Hagai, Eli Eyal, Sigal Melamed-Gal
  • Publication number: 20170209428
    Abstract: The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.
    Type: Application
    Filed: August 31, 2016
    Publication date: July 27, 2017
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Brian D. Smith, Marc Rudoltz
  • Publication number: 20170209429
    Abstract: The present invention relates to an abuse deterrent transdermal patch.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 27, 2017
    Inventors: Audra Lynn STINCHCOMB, Dana Carmel HAMMELL, Stan Lee BANKS, Josh ELDRIDGE, Miroslaw Jerzy GOLINSKI